The Power of Three G’s: Retatrutide Phase 2 Results in Participants with T2DM, Obesity & NAFLD
Time: 9:30 am
day: Seminar A- AM tracks
Details:
- Delving into Retatrutide (LY3437943): a triple agonist of the GIP, GLP-1 and glucagon receptors to better understand its mechanism of action
- Showing clinically meaningful improvements in glycemic control and robust reductions in body weight in a Phase 2 study in participants with T2DM
- Demonstrating substantial reductions in body weight in a Phase 2 study in participants with obesity or overweight with ≥1 weight-related condition and significant reductions in liver fat in a substudy in participants with NAFLD
